Close Menu

NEW YORK – Enzo Biochem reported after the close of the market on Tuesday that its fiscal fourth quarter revenues fell 8 percent year over year, reflecting new, "sharply lower" industry-wide reimbursement rates under the Protecting Access to Medicare Act (PAMA).

For the three months ended July 31, the diagnostics company said total revenues sank to $20.9 million from $22.8 million a year earlier.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.